415 related articles for article (PubMed ID: 32811190)
21. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
Cohen F; Yuan H; Silberstein SD
BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
[TBL] [Abstract][Full Text] [Related]
22. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
23. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
24. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Favoni V; Giani L; Al-Hassany L; Asioli GM; Butera C; de Boer I; Guglielmetti M; Koniari C; Mavridis T; Vaikjärv M; Verhagen I; Verzina A; Zick B; Martelletti P; Sacco S;
J Headache Pain; 2019 Mar; 20(1):27. PubMed ID: 30866804
[TBL] [Abstract][Full Text] [Related]
25. Ubrogepant for the treatment of migraine.
Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
[TBL] [Abstract][Full Text] [Related]
26. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
Charles A; Pozo-Rosich P
Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
[TBL] [Abstract][Full Text] [Related]
27. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
Suzuki K; Suzuki S; Fujita H; Sakuramoto H; Shioda M; Hirata K
Neuropsychopharmacol Rep; 2024 Jun; 44(2):482-484. PubMed ID: 38602109
[TBL] [Abstract][Full Text] [Related]
28. Are antimigraine drugs that influence CGRP levels justified?
Piechal A; Domitrz I; Kurkowska-Jastrzębska I; Mirowska-Guzel D
Pharmacol Rep; 2019 Aug; 71(4):624-635. PubMed ID: 31181379
[TBL] [Abstract][Full Text] [Related]
29. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
Villalón CM; Olesen J
Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
Jiang Y; Huang ZL
Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
[TBL] [Abstract][Full Text] [Related]
31. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications.
de Vries Lentsch S; Rubio-Beltrán E; MaassenVanDenBrink A
Maturitas; 2021 Mar; 145():73-77. PubMed ID: 33541566
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
33. Blocking CGRP in migraine patients - a review of pros and cons.
Deen M; Correnti E; Kamm K; Kelderman T; Papetti L; Rubio-Beltrán E; Vigneri S; Edvinsson L; Maassen Van Den Brink A;
J Headache Pain; 2017 Sep; 18(1):96. PubMed ID: 28948500
[TBL] [Abstract][Full Text] [Related]
34. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
Do TP; Al-Saoudi A; Ashina M
Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
[TBL] [Abstract][Full Text] [Related]
35. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
36. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.
Edvinsson L
J Intern Med; 2022 Oct; 292(4):575-586. PubMed ID: 35532284
[TBL] [Abstract][Full Text] [Related]
38. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Pellesi L; Guerzoni S; Pini LA
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
[TBL] [Abstract][Full Text] [Related]
40. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
Chen ST; Wu JW
Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
